Witness Testimony

Dr. Christopher Flowers, a radiologist and clinical researcher, testified regarding his role as medical lead for a volunteer team reviewing Pfizer COVID-19 vaccine regulatory documents obtained through Freedom of Information requests. He described the team’s analysis of clinical trial data and post-marketing safety reports, highlighting concerns about protocol amendments during Phase 3 trials, limited early safety follow-up, and the timing and transparency of data releases. He questioned the adequacy of regulatory review processes and emphasized the importance of independent analysis free from conflicts of interest.
He presented findings from early post-authorization safety reports, stating that significant numbers of adverse events were reported within days of vaccination, including neurological, cardiovascular, and reproductive-related events. He noted higher reported rates of serious adverse events among women, particularly those of working age, and discussed concerns about menstrual irregularities, fertility, myocarditis in younger populations, and cases involving children. He also raised concerns about reported deaths during clinical trials and the classification and reporting of adverse events.
Dr. Flowers further addressed issues related to the mRNA lipid nanoparticle platform, including biodistribution data from animal studies, manufacturing variability, and potential contamination. He questioned the sufficiency of long-term safety data, the transparency of ingredient disclosure, and the independence of regulatory agencies. He concluded that, in his professional opinion, the harms associated with the vaccine outweighed the benefits and recommended suspension of its use pending more comprehensive and independently reviewed safety data.